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Abstract It has been shown that treatment of mice preinfected with Mycobacte-
rium tuberculosis with spin NO traps (iron complexes with diethyldithiocarbamate)
enables detection of large amounts of NO in internal organs 2 and 4 weeks after
infection (up to 55–57 lmol/kg of wet lung tissue accumulated with spin NO traps
during 30 min). The animals were infected with the drug-sensitive laboratory strain
H37Rv and a clinical isolate nonrespondent to antituberculous drugs (the multidrug-
resistant strain of M. tuberculosis) obtained from a patient with an active form of
tuberculosis. Two weeks after infection with the multidrug-resistant strain, the NO
level in the lungs, spleen, liver and kidney increased sharply concurrently with
slight lesions of lung tissue. A reverse correlation, i.e., low level of NO in the lungs
and other internal organs and extensive injury of lung tissue, was established for
H37Rv-infected mice. Four weeks after infection, NO production in the lungs
increased dramatically for both M. tuberculosis strains resulting in 80–84% damage
of lung tissue. The lesion is suggested to be due to the development of defense
mechanisms in M. tuberculosis counteracting NO effects.
1 Introduction
It was found that a combination of nitric oxide (NO) with active oxygen species
affords effective protection of animals and men against pathogenic effects of
mycobacteria, including the tuberculous pathogen Mycobacterium tuberculosis
(Mtb)[ 1–16]. Localization of this pathogen in the lungs and other internal organs is
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Magnetic Resonanceaccompanied by inﬁltration of immunocompetent cells stimulated as a result of
immune reaction with the pathogenic microorganism. This process initiates the
synthesis of inducible NO synthase (NOS2), producing NO from L-arginine in
immunecompetent cells (macrophages, neutrophils, etc.) [2–8, 11–14, 16]. The
cytotoxic activity of NO produced by these cells triggers the formation of a
protective system in Mtb able to resist the NO attack. The proteins constituting the
system induce NO chemical modiﬁcation. In addition, Mtb inhibits NOS2
expression in immunocompetent cells or eliminates the enzyme from the sites of
intracellular mycobacterial residence, such as phagocytes [3, 12, 15, 17–28].
Therefore, quantitative assessment of NO levels in target tissues of Mtb-infected
animals acquires special importance because it sheds additional light on mecha-
nisms of interaction between immune cells and Mtb. Moreover, this problem has
never been studied before. In the present investigation, this goal was achieved by
application of the spin NO trap method, which was developed for the ﬁrst time by
our research group and employed hydrophobic iron complexes with diethyldithio-
carbamate (DETC) as NO traps [29, 30]. Binding of NO to these complexes yields
electron paramagnetic resonance (EPR)-active mononitrosyl iron complexes with
DETC (MNIC–DETC) localized in hydrophobic compartments of the cell. Such
type of MNIC–DETC localization justiﬁes ex vivo approach for the estimation of
NO levels in the organs isolated from animal organism. The intensity of EPR signals
elicited by MNIC–DETC is commensurate with their concentration and, as a
consequence, with tissue levels of NO. The experiments were carried out on mice
infected with two Mtb strains, viz., sensitive and resistant to currently known
antituberculous drugs. Measurements of NO levels in tissues were performed 2 or
4 weeks after infection. The degree of lung tissue injury was estimated in parallel
experiments using a histological method.
2 Materials and Methods
2.1 Materials
The following reagents were used: DETC (Sigma, USA), N-methyl-D-glucamine
dithiocarbamate (MGD, synthesized as described in Ref. [31]). Ferrous sulfate was
from Fluka (Switzerland). Gaseous NO was obtained by a reaction of FeSO4 with
NaNO2 in 0.1 M HCl. The escaping NO gas was additionally puriﬁed by low-
temperature sublimation in an evacuated glass system. The MNIC–MGD solutions
of known concentrations were synthesized as described in Ref. [31].
2.2 Animal Studies
The experiments were carried out on 60 inbred male albino mice weighing 18–20 g.
The animals were infected with two different strains of Mtb (5 9 10
4 cells per
animal, intravenously), viz., a drug-sensitive laboratory strain (H37Rv) and an
anonymous clinical isolate nonrespondent to the majority of existing antitubercu-
lous drugs (guaniazide, streptomycin, ridamycin). The latter represented a
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123multidrug-resistant Mtb strain obtained from a patient with active tuberculosis at
Research Institute for Phthisiopulmonology, I.M. Sechenov Moscow Medical
Academy, Moscow. Two and four weeks after infection, the animals were sacriﬁced
by cervical dislocation; lung tissue was extracted and analyzed histologically. For
histological analysis, small tissue fragments were ﬁxed in Bowen ﬂuid; after ﬁxation
and sampling, the test material was ﬁxed in parafﬁn. Serial slides were prepared
from bulk parafﬁn using hematoxylin and eosin as dyes. The volumetric density
(vol %) of tuberculous pneumonia foci in histological slides was calculated by
the points rating method based on the use of the Avtandilov grid test (1009
magniﬁcation) [32].
In experiments designed to measure the NO content in internal organs (lungs,
spleen, liver and kidney) 30 min before killing, infected animals were additionally
treated with DETC (500 mg/kg, intraperitoneally) and an iron–citrate complex
(37.5 mg/kg FeSO47H2O ? 187.5 mg/kg sodium citrate, intramuscularly into the
leg). On entering target organs, iron and DETC initiated the formation of NO spin
traps and lipophilic iron–DETC complexes localized in hydrophobic cell
compartments. Their binding to NO yielded paramagnetic MNIC–DETC detect-
able by the EPR method [29, 30, 33]. After extraction, internal organs were frozen
in liquid nitrogen for storage and measurement of EPR spectra. This approach
enabled 30-min measurement of NO generation rates in target organs and NO
accumulation in spin traps. In parallel experiments, the rates of formation of
paramagnetic nitrosyl hemoglobin complexes were determined in animal blood
using the EPR method.
Previously, it was found that high values of rate constants for NO binding to
iron–DETC complexes and high concentration of these NO traps in animal organs
are prerequisite to high rates of NO binding by these traps [33]. The latter markedly
exceeded the rates of NO trapping by endogenous compounds, e.g., superoxide or
hemoglobin. This suggests that the method for NO detection adequately reﬂects NO
production in living organisms without artifact effects of potential NO scavengers.
2.3 EPR Measurements
EPR spectra were measured in frozen animal organs (lungs, liver, spleen and
kidney) and blood at 77 K on a microwave spectrometer ESC-106 (Bruker,
Germany; microwave power, 5 mW; magnetic ﬁeld modulation amplitude, 0.5 mT).
The concentration of paramagnetic centers of experimental samples was determined
from integral intensities of EPR signals by comparing double integrals of EPR
signals to those of experimental and standard samples. Frozen solutions of MNIC–
MGD of known concentrations were used as standards.
2.4 Statistic Treatment of Experimental Data
The data were presented as mean ± standard error of the mean (SEM) of ﬁve
individual observations from different mice (p\0.01 vs. corresponding differences
among the groups of rats).
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The EPR signals of MNIC–DETC recorded in the lungs, spleen, liver and kidney
tissues of mice 2 weeks after their infection with the drug-resistant or drug-sensitive
strain of Mtb are shown in Fig. 1. Regarding their shape and spectroscopic
characteristics (g = 2.035, presence of a triplet hyperﬁne structure determined by
interaction of the unpaired electron with the nitrogen nucleus of NO, etc.), these
signals are identical with those reported previously for MNIC–DETC [29, 30, 33–
41]. The concentrations of NO incorporated into MNIC–DETC in lung, spleen, liver
and kidney tissues during 30 min estimated from the corresponding EPR signals are
listed in Table 1. For comparison sake, Table 1 provides the NO content in
respective organs of control (noninfected) animals. From Table 1 and Fig. 1,i t
follows that infection of mice with the drug-resistant Mtb strain caused a dramatic
increase in the NO level in all internal organs as early as 2 weeks after infection.
The pathological changes were especially well-pronounced in the spleen and the
lungs, most probably due to speciﬁc localization of Mtb in these organs.
According to previously published data [2, 8, 11–14, 16], NO synthesis in tissues
of Mtb-infected mice was localized in immunocompetent cells (macrophages,
neutrophils) and occurred via an L-arginine-dependent pathway. This hypothesis
was veriﬁed in experiments in which mice infected with the multidrug-resistant
strain of Mtb were treated with the nonspeciﬁc NOS inhibitor nitro-L-arginine at the
end of the second postinfection week. The inhibitor was administered to animals in
the dose of 50 mg/animal 30 min before the spin trap injection. As a result, the
intensity of the EPR signal of MNIC–DETC in mouse lungs diminished by 65–67%.
Fig. 1 EPR spectra of lung (A), spleen (B), liver (C) and kidney (D) MNIC–DETC measured 2 weeks
after infection of mice with the multidrug-resistant strain (left panel) or the drug-sensitive strain (right
panel). The ampliﬁcations of the EPR spectrometer were 10
4 (A); 10
4 (B); 10
5 (C); or 2 9 10
5 (D). The
spectra were recorded at 77 K, microwave power of 5 mW, and modulation amplitude of 0.5 mT
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123Histological analysis of lung tissues carried out at the end of the second week
after infection of mice with the multidrug-resistant strain of Mtb revealed signs of
microfocal interstitial pneumonia with major focal inﬁltration of immunocompetent
cells into alveolar septae (Fig. 2, left panel). Judging from EPR data (Fig. 1;
Table 1), this gave rise to enhanced production of NO in the lungs to an extent
sufﬁcient to suppress Mtb proliferation. Histological data suggest that the
volumetric density of tuberculous lesions of lung tissue at the end of the second
week after infection of mice with Mtb dropped down to 7.1 ± 1.1 vol% (Table 2).
In mice infected with the drug-sensitive strain of Mtb, notable increases in NO
levels were found only in the spleen and lungs 2 weeks after infection. Noteworthy,
these increases were substantially lower than in mice infected with the multidrug-
resistant strain of Mtb (Table 1). The difference could be due to less intensive
inﬁltration of NO-generating immunocompetent cells into the aforesaid organs in
mice infected with the drug-sensitive strain of Mtb. However, histological analysis
of lung tissues revealed signs of interstitial pneumonia and pronounced diffuse-focal
inﬁltration of immunocompetent cells into alveolar walls (Fig. 2, right panel). The
volumetric density of the pathological foci was 54.3 ± 9.0 vol% (Table 2). This
Table 1 NO accumulation (30 min) in internal organs of mice infected with Mtb (lmol/kg of tissue)
Tissue Control (mean ± SEM),
lmol/kg
Multidrug-resistant strain
(mean ± SEM), lmol/kg
Drug-sensitive H37Rv strain
(mean ± SEM), lmol/kg
Week 2 Week 4 Week 2 Week 4
Lungs 0.5 ± 0.4 31.6 ± 9.7 54.6 ± 21.5 4.6 ± 1.8 57.3 ± 24.2
Spleen 1.0 ± 0.5 93.8 ± 26.9 51.4 ± 16.4 13.2 ± 4.6 37.2 ± 12.8
Liver 2.0 ± 0.5 17.6 ± 4.8 6.0 ± 2.3 0.7 ± 0.3 5.3 ± 2.4
Kidney 1.1 ± 0.4 5.9 ± 2.7 3.6 ± 1.4 0.2 ± 0.1 1.2 ± 0.5
Fig. 2 Mouse lungs examined 2 weeks after infection with the drug-resistant (left panel) and drug-
sensitive (right panel) strains of Mtb. Left panel the arrows indicate typical small interstitial pneumonia
foci with slight focal inﬁltration of interalveolar septae by immunocompetent cells. Right panel interstitial
pneumonia manifested as strong diffuse-focal inﬁltration of interalveolar septae by immunocompetent
cells (indicated by arrows)
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123ﬁnding allowed us to suggest that inﬁltration of immune cells into lung tissues of
mice infected with the drug-sensitive strain of Mtb did not prevent proliferation of
mycobacteria in lung tissues, which correlated with the low level of NO generation
in these cells. The reason is still unclear; it is not excluded that this Mtb strain
suppresses NO production in immunocompetent cells, at least within the ﬁrst two
postinfection weeks. According to literature data, such capability is speciﬁc only for
certain Mtb strains [3, 12, 15, 17, 18].
The sharp increase in the NO level in internal organs of mice infected with the
drug-sensitive strain of Mtb in the subsequent 2 weeks (Table 1) was especially
apparent in the lungs and spleen tissues during the ﬁrst 2 weeks. In mice infected
with the multidrug-resistant strain of Mtb, NO elevation was observed on week 4
only in the lungs, being decreased in other organs (see Table 1). According to
histological data (not shown), the rate of proliferation of Mtb and the degree of lung
tissue lesion increased sharply in mice infected with both Mtb strains (Table 2).
The EPR spectra of blood of mice infected with the multidrug-resistant strain of
Mtb displayed the presence, in addition to MNIC–DETC lines, of broader EPR
signals corresponding to nitrosyl hemoglolbin complexes (Hb–NO) at g-factor
values of 2.07 and 1.98 (Fig. 3A and B). For comparison sake, Fig. 3D contained a
more intense EPR signal for Hb–NO recorded in blood sera of mice treated with
gaseous NO. The concentration of Hb–NO complexes in the blood of mice infected
with the multidrug-resistant strain of Mtb increased in a time-dependent manner,
being equal to 0.9 ± 0.4 lmol/l 2 weeks after infection and to 2.3 ± 0.9 lmol/l
4 weeks after infection. In addition to Hb–NO and MNIC–DETC signals, the EPR
spectrum displayed in Fig. 3a has four components (designated as a, b, c and d,
respectively) corresponding to the hyperﬁne structure of the EPR signal of Cu
2?–
DETC complexes [29]. The latter was also present in the EPR spectrum of control
animals treated with MNIC––DETC (Fig. 3C). No EPR signals of Hb–NO or
MNIC–DETC were found in blood of animals infected with the drug-sensitive strain
of Mtb.
4 Discussion
The data obtained suggest that the use of iron complexes with DETC as spin NO
traps allows 30-min monitoring of NO formation in animals infected with Mtb.I n
mice infected with the multidrug-resistant strain of Mtb, high NO concentrations
were noted even on the second postinfection week and were accompanied by
inhibition of proliferation of the tuberculous pathogen in lung tissue as can be
Table 2 Degree of lung tissue lesion in mice infected with Mtb
Tissue Multidrug-resistant (wild)
strain (mean ± SEM), %
Drug-sensitive (laboratory)
strain (H37Rv) (mean ± SEM), %
Week 2 Week 4 Week 2 Week 4
Lung 7.0 ± 1.1 77.9 ± 8.3 54.3 ± 9.0 84.3 ± 10.6
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123judged from low degree of lesion of this organ. In animals infected with the drug-
sensitive strain of Mtb, NO elevation occurred more slowly and was manifested in
severe lesions of lung tissue as early as 2 weeks after infection. This suggests that
NO production by immunocompetent cells inhibits, at least on the initial steps of
infection, the proliferation of the tuberculous pathogen. This ﬁnding is in good
agreement with the previously reported data and reﬂects the cytotoxic and protective
effects of NO against Mtb [1–16].
Noteworthy, on week 4 the beneﬁcial therapeutic effect of enhanced NO
synthesis was absent in both animal groups despite the high content of this cytotoxic
agent (Table 1): the extent of lung lesion increased to 80–84% (Table 2). Such a
high degree of lung injury can be attributed to the ability of Mtb to trigger the
synthesis of proteins able to modulate NO activity and to make NO nonhazardous
for mycobacteria. According to literature data, the role of such proteins in Mtb is
played by ﬂavohemoglobin homologues [12, 18] or truncated Hb (HbN) [12, 22,
26]. The latter catalyzes oxygen-mediated oxidation of NO to nitrates, whereas
ﬂavohemoglobin additionally catalyzes NO reduction to N2O under anoxia.
Enhanced production of NO in animals infected with the multidrug-resistant
strain was accompanied by the formation of circulating nitrosyl hemoglobin
complexes. Interestingly, the concentration of the latter increased with time. No
Fig. 3 EPR spectra of mouse blood measured on week 4 (A) or week 2 (B) after infection of animals with
the multidrug-resistant strain and added DETCciron complexes. C EPR spectrum of blood from
noninfected mice treated with DETC–iron complexes. D EPR spectrum of Hb–NO isolated from mouse
blood treated with gaseous nitric oxide used at concentration corresponding to 1.5 lmol of Hb–NO per 1 l
of blood. a–d Components of the hyperﬁne structure of the Cu
2?–DETC EPR signal. Spectra were
recorded at 77 K, microwave power of 5 mW, modulation amplitude of 0.5 mT and 5 9 10
5 (A–C)o r
1 9 10
5 (D) ampliﬁcation of the EPR spectrometer
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123such complexes were found in the blood of animals infected with the drug-sensitive
strain, even on week 4 after infection against the background of dramatically
enhanced NO synthesis (Table 1). However, this ﬁnding needs further veriﬁcation.
By week 4, NO synthesis in the liver, spleen and kidney of mice infected with the
multidrug-resistant strain of Mtb was sharply decreased concomitantly with notably
increased Hb–NO content. Enhanced synthesis of NO was observed only in lung
tissue (Table 1). It is not excluded that the low level of NO synthesis in other organs
was due to depletion of intracellular pools of the NOS2 substrate L-arginine in
immunocompetent cells. No such event took place in immune cells of mice infected
with the drug-sensitive strain Mtb, enhanced NO production in which was noted
only on weak 4 after infection (Table 1).
It is noteworthy that high level of NO synthesis observed in lung tissue on week 4
after infection of mice with both Mtb strains amounted to 55–57 lmol/kg of wet
tissue during the process of NO spin trapping (30 min). The value approximated the
NO level established previously by the iron–dithiocarbamate method in liver tissues
(100 lmol/kg of wet tissue) of mice treated with a bacterial lipopolysaccharide
(LPS). The latter is known to initiate inﬂammatory processes and enhanced NO
synthesis in animal organisms [35, 42]. Interestingly, in lung tissues of LPS-treated
animals the NO level did not exceed 10 lmol/kg of wet tissue.
This fact notwithstanding, the high level of the NO production in lung tissues of
Mtb-infected mice was too low to overcome the immune barrier of mycobacterial
cells formed in response to NO attack. It was tempting to speculate that this
protective barrier can be overcome at higher rates of NO accumulation in the
infected lung. One of the approaches consists in treatment of infected animals with
the NOS2 substrate L-arginine; the alternative approach consists in injection of
exogenous NO donors. Numerous attempts to use NO-ates or S-nitrosothiols as NO
donors were undertaken in previous studies [1, 9, 43–45]. However, the lack of
strong evidence suggests that NO generation induced by these factors is short-term
and insufﬁcient for stimulating cytotoxic activity of NO. The NO thus generated is
rapidly deactivated in a reaction with the superoxide, eventually resulting in fast
(within several seconds) decomposition of the peroxynitrite formed. The role of an
efﬁcient long-acting NO donor can be played by low-molecular dinitrosyl iron
complexes (DNIC). On entering the organism, these complexes are converted into
protein-bound DNIC as a result of a transfer of Fe(NO)2 groups from low-molecular
DNIC to thiol groups of proteins. Protein-bound DNIC are more stable than their
low-molecular-weight analogs, which are prerequisite to long-term (up to 60 min
and longer periods) release of NO into the intracellular space [46, 47].
Increased sensitivity of the multidrug-resistant Mtb strain to cytotoxic effect of
NO (at least during the ﬁrst 2 weeks after infection) and its high resistance to the
main antituberculous drugs (guaniside, streptomycin, ridamycin) suggest that the
effects of the latter on mycobacteria is not coupled with initiation of NO synthesis in
immunocompetent cells. It is not excluded that NO produced by immunocompetent
cells or efﬁcient exogenous donors exerts a more potent protective antimycobacterial
effect on both Mtb strains than the aforementioned drugs. Interestingly, the drug-
sensitive Mtb strain appeared to be resistant, at least within the ﬁrst two postinfection
weeks, to NO-producing immunocompetent cells. The results of present study
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123strongly suggest that such an effect is due to the ability of this Mtb strain to inhibit
NO production, as was established earlier for several Mtb strains [3, 12, 15, 17, 18].
However, this hypothesis demands further veriﬁcation and experiment.
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